Amphastar Pharmaceuticals

AMPH

Market cap $1.28B

Overview Fund Activity

27.59 USD

+0.61

2.26%

At close Updated Sep 18, 1:37 PM EDT

1 day

2.26%

5 days

-4.4%

1 month

-7.29%

3 months

8.88%

6 months

0.84%

Year to date

-24.12%

1 year

-44.58%

5 years

40.98%

10 years

87.3%

About: Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Employees: 2,028

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

25% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 73

17% more call options, than puts

Call options by funds: $447K | Put options by funds: $381K

8% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 40

0% more funds holding

Funds holding: 241 [Q1] → 241 (+0) [Q2]

0.52% less ownership

Funds ownership: 69.86% [Q1] → 69.34% (-0.52%) [Q2]

22% less capital invested

Capital invested by funds: $965M [Q1] → $751M (-$213M) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$25

9% downside

Avg. target

$31

12% upside

High target

$36

30% upside

3 analyst ratings

1 positive

33%

2 neutral

67%

0 negative

0%

B of A Securities Jason Gerberry	$32	Neutral Maintained	26 Aug 2025
Needham Serge Belanger	$36	Buy Upgraded	12 Aug 2025
Piper Sandler David Amsellem	$25	Neutral Maintained	8 Aug 2025

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Is the Options Market Predicting a Spike in Amphastar Pharmaceuticals Stock?

Investors need to pay close attention to AMPH stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Amphastar Pharmaceuticals Stock?

Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / August 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025, at 12:45 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.'s AMPH Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials, previously referred to as AMP-002.

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.

Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today announced that it has entered into an exclusive license agreement ("Agreement") with Nanjing Anji Biotechnology Co., Ltd. ("Anji") for the development, manufacturing, use, and commercialization of three proprietary peptides, ("Licensed Products"), in the United States and Canada ("Territory").

Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.

Amphastar Announces FDA Approval for Iron Sucrose Injection, USP

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer ® for the treatment of iron deficiency anemia in patients with chronic kidney disease RANCHO CUCAMONGA, CA / ACCESS Newswire / August 11, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials, previously referred to as AMP-002. Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD).

Amphastar Announces FDA Approval for Iron Sucrose Injection, USP

Zacks Investment Research

Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication Tony Marrs - Executive VP of Regulatory Affairs & Clinical Operations William J. Peters - CFO, Executive VP of Finance, Treasurer & Director Conference Call Participants David A.

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Amphastar (AMPH) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amphastar (AMPH) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.94 per share a year ago.

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025

- Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025 - GAAP net income of $31.0 million, or $0.64 per share, for the second quarter - Adjusted non-GAAP net income of $40.9 million, or $0.85 per share, for the second quarter - Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / August 7, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended June 30, 2025.

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025

See News Rankings

Charts implemented using Lightweight Charts™